TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cutaneous Scarring of Scalpel Versus Cautery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Inclusion Criteria:~1. Patients undergoing primary, elective panniculectomy.~2. Patients must voluntarily be enrolled in the study after informed consent.~3. Patients must be in relative good health and have adequate nutrition.~4. Patients of all races and genders will be included.~5. Patients must agree to refrain from the use of topical scar products during the study period.~Exclusion Criteria:~1. Under the age of 18 years old~2. Patients with previous history of hypertrophic or keloid scarring~3. Patients presenting for scar revision~4. Patients presenting for a non-elective surgery~5. Patients with chronic immunosuppression or wound healing problems~6. Currently taking medications that interfere with wound healing such as corticosteroids, anti-coagulants (aspirin or NSAIDs), vasoconstricting agents (adrenaline or ergotrate), anti-cancer drugs, or colchicine for gout,~7. Use of any tobacco products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cautery Arm (Type: ACTIVE_COMPARATOR): Cautery to make skin incision
- Scalpel Incision (Type: ACTIVE_COMPARATOR): Scalpel to make skin incision

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cannabis and Thought Disorder in Schizophrenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 18 and 65~* Meeting the DSM-5 criteria for schizophrenia~* Cannabis user group: - Smoking at least two days per week during the previous months~* Displaying positive urine screen for cannabis~* Non-cannabis user group: - No episode of cannabis smoking during the previous month~* Negative urine screen for cannabis + no lifetime criteria for cannabis use disorder (assessment by an addiction specialist).~Exclusion Criteria:~* Current criteria for axis-1 psychiatric disorder other than schizophrenia~* Current criteria for any other substance use disorder except for nicotine use disorder~* Any contraindication for MRI~* Tutorship or curatorship~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cannabis users (Type: EXPERIMENTAL): Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.
- Non- cannabis users (control group) (Type: ACTIVE_COMPARATOR): Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of a 30-day Automated Text Messaging Intervention on Hospital Based Acute Care Encounters Following Ileostomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18-90 years of age with phone or text receiving device access.~* English speaking~* Patients undergoing ileostomy surgery~Exclusion Criteria:~* Patients who do not have phone or text receiving device access~* Patients mentally unable to provide consent for the study~* Patients who do not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- EpxOstomy (Type: EXPERIMENTAL): Post-operative ileostomy patients will receive the study intervention for 30 days following discharge from the hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, at least 18 years of age~* History of histologically confirmed NHL as assessed per medical record review.~* At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or FDG PET/CT.~* Recommended to start lenalidomide.~* Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.~Exclusion Criteria:~* Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit.~* Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.~* Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~1. Male or female subjects aged 18 years and above, who have severe cancer pain.~2. Subjects who require a strong opioid by subcutaneous infusion to stabilise and manage their cancer pain effectively.~3. Subjects who give written informed consent to participate in the study.~4. Subjects who agree to their primary care physician being informed of their participation in the study.~5. Subjects who consent to processing of their trial data according to the requirements of the UK Data Protection Act 1998.~Exclusion Criteria~1. Subjects who are pregnant, lactating or in the Investigators opinion are at risk of conceiving and are not using adequate contraception measures.~2. Subjects with known hypersensitivity (allergic reaction) to oxycodone, any other opioids or any of the excipients.~3. Subjects who are planned to receive chemotherapy during the study treatment period or are currently receiving continuous i.v. chemotherapy infusion.~4. Subjects with neutropenia, thrombocytopenia or coagulation disorders.~5. Subjects with any contraindications to oxycodone as outlined in the Investigator Brochure or Summary Product Information sheet for oxycodone.~6. Subjects who are currently participating in another clinical research study involving a new chemical entity.~7. Subjects whom the Investigator believes to be medically unfit to receive the study medication, or unsuitable for any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oxytocin in Adolescents With Autism Spectrum Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age between 11 years 11 months and 17 years 11 months~* Autism spectrum disorder according to DSM V~* ADI \> 10~* WISC \> 70~* CARS \> 30~Exclusion Criteria:~* Female~* presence of genetic and neurological syndromes~* changes in drugs or in any intervention during the study

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- OCYTOCINA - SPRAY NASAL (Type: ACTIVE_COMPARATOR): OCYTOCINA - SPRAY NASAL - 24Ui twice per day for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - twice per day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Incidentally Discovered Pancreatic Cysts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cyst between 1-3cm~* No evidence of a mural nodule, solid component, or septations in the cyst~* For patients with multiple cysts, the largest will be evaluated~Exclusion Criteria:~* Any imaging or cytology concerning for malignancy~* Pancreatic Pseudocyst~* Gross Cyst \>3cm as measured on MRCP~* Clinically active pancreatitis or serum amylase or lipase \>3x upper limit of normal~* Coagulopathy (INR\>1.5, PTT\>100, Platelets\<50K)~* Inability to tolerate conscious sedation and endoscopy~* Rated ASA IV or greater~* Prior EUS and aspiration of the pancreatic cyst~* Breast feeding~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: NO_INTERVENTION): Observation of pancreatic cysts
- B (Type: EXPERIMENTAL): Ethanol lavage of pancreatic cysts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cell Responses to IFN-gamma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Normal volunteers with no evidence of skin disease OR diagnosis of plaque type psoriasis for at least 6 months~* 18 years of age or greater~* For women of childbearing potential or in men whose partners may become pregnant, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study. Acceptable methods of contraception include use of a condom; abstinence; use by sexual partner of oral implantable or injectable contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap; or a sterile sexual partner~Exclusion Criteria:~* Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis~* Clinically significant psoriasis flare during screening or on the first treatment day~* Hypersensitivity to IFN-g or E. coli derivatives~* Pre-existing, uncontrolled myelosuppression, cardiac disease, seizure disorders, compromised central nervous system function or multiple sclerosis~* History of malignancy, clinically significant renal insufficiency, poorly controlled medical conditions that would increase the risks~* Presence of malignancy within the past 5 years, including lymphoproliferative disorders. Subjects with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled.~* Pregnancy or lactation. As the risk of IFN-g in pregnancy is unknown, pregnant women will be excluded from the study.~* Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Aged 18 years or older~* Pathologically confirmed invasive unilateral breast carcinoma~* A clinical T1-2 tumour (including multifocal or multicentric breast cancer)~* Will be or is treated with mastectomy~* Clinically node negative: no signs of axillary lymph node metastases at physical examination and preoperative axillary ultrasound (or negative cyto-/histopathology)~* Sentinel lymph node procedure and its pathologic evaluation should be performed according to the Dutch breast cancer guideline~* pN1mi(sn) or pN1(sn): at least one and a maximum of three axillary sentinel lymph nodes containing micro- and/or macrometastases~* Written informed consent~Exclusion Criteria:~* Clinically node positive pre-operative~* Sentinel lymph nodes only containing isolated tumour cells (\<0.2 mm)~* Solitary parasternal sentinel lymph node metastasis (pN1b)~* Bilateral breast cancer~* Irradical resection of primary tumour at time of randomization (applicable in case the mastectomy is performed before randomization)~* Evidence of metastatic disease~* History of invasive breast cancer~* Previous treatment of the axilla with surgery or radiotherapy (except surgery for hidradenitis suppurativa or for other superficially located skin lesions, such as naevi)~* Pregnant or nursing~* Other prior malignancies within the past 5 years (except successfully treated basal cell and squamous cell skin cancer, carcinoma in situ of the cervix or carcinoma in situ of the ipsilateral or contralateral breast) or unsuccessfully treated malignancies \> 5 years before randomization~* Unable or unwilling to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Completion axillary treatment (Type: ACTIVE_COMPARATOR): Completion axillary treatment according to the Dutch breast cancer guideline
- No completion axillary treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EVENT: Hydrotherapy and Deep Venous Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* both sexes;~* 18 years old and more;~* clinical indication of thermal cure (first phase of deep venous thrombosis authenticated by unilateral venous echo-doppler~* curative anticoagulant treatment more than 3 month;~* oedema and/or spontaneous pain with functional discomfort;~* available for a thermal cure during 18 days and a follow-up period of 36 month;~* voluntary to participate to the study, informed consent form signed after appropriate information;~* affiliation to the social security system or equivalent;~* no previous participation to a thermal cure (in the indication of phlebology)~Exclusion Criteria:~* isolate distal thrombosis;~* asymptomatic thrombosis;~* cutaneous ulcer of lower limb;~* refusal to consent;~* refusal to benefit of thermal cure;~* contra-indication to hydrotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): immediate thermal cure (1st year)
- 2 (Type: SHAM_COMPARATOR): late thermal cure (2 years)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Ciclesonide for Outpatients With COVID19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Symptomatic adult patients positive by PCR for COVID-19 within 5 days of enrollment with fever, cough, or shortness of breath. Provision of Informed Consent~At day 0, patients should be at home~Exclusion Criteria:~* Already on inhaled corticosteroid medication~* Currently using systemic steroids (oral or intravenous or intramuscular such as Prednisone) or use of steroids 7 days prior to enrolment~* Severely ill patients at enrollment (i.e., admitted to ICU at admission)~* Unable to self-administer the inhaler~* Known or suspected pregnancy and breastfeeding~* Known allergy to study medication or its components (non-medicinal ingredients; including lactose allergy (type I))~* Patients with untreated fungal, bacterial, or tubercular infections of the respiratory tract~* Current hospitalization~* Current use of oxygen at home or in the hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ciclesonide inhaled and nasal (Type: ACTIVE_COMPARATOR): Intranasal ciclesonide BID 50mcg BID to each nostril and inhaled ciclesonide 600mcg BID x 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Cooling for Patients With Excel Cryo Cooling System in Intracerebral Hemorrhage (ICH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with brain injury in the Neurological ICU.~2. Consent from the patient or surrogate decision maker.~3. Warfarin induced intracerebral hemorrhages only after correction of INR to \<1.4.~Exclusion Criteria:~1. Cerebellar hemorrhages.~2. Moribund state where the physician team doesn't believe the patient will survive.~3. Patients who are being cared for with the intent of making them comfortable. DNR-CC (by Ohio law).~4. Known history of a blood dyscrasia such as CLL or essential thrombocytosis that could affect inflammation.~5. Known significant carotid artery stenosis (known \>50% stenosis by history or incidental hospital imaging). This will not be specifically tested. Patients found to have significant stenosis later in the hospital stay will have their data interpreted separately as well as in the total group.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Excel Cryo Cooling System Collar (Type: OTHER): An Excel Cryo Cooling System collar will be placed around the neck for a 2 hour neck cooling period. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level and pressure both in the head and in the blood.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Performance of Muscle Activation for Critical Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is enrolled within 60 hours of admission to the ICU~* Patient expected to be subject to bedrest in the ICU for \> 96 hours~Exclusion Criteria:~* Patient is age \< 18 years at time of consent~* Patient is pregnant~* Patient is moribund~* Patient has an implanted pacemaker/defibrillator~* Patient has a documented diagnosis of epilepsy~* Patient has implanted femoral rods~* Patient has leg or pelvic trauma that limits mobility~* Patient has recent trauma resulting in GCS \< 5~* Patient lacks ability to walk without assistance prior to acute ICU admission~* Patient has neuromuscular disease or abnormalities~* Patient is morbidly obese (BMI \> 40)~* Patient has a cognitive impairment or inability to follow commands prior to acute ICU admission~* Patient was transferred after \> 48 hours at another acute care institution~* Enrollment in another investigational device or drug trial that could compromise the conduct or results of the study~* Evidence of disease or condition that, in the opinion of the physician, may compromise the conduct of or results of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Activation Treatment (Type: EXPERIMENTAL): None
- Usual Care (Type: NO_INTERVENTION): This arm will not receive any study-motivated intervention. Subjects will receive usual care, but will participate in outcomes assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues